US Bancorp DE Lowers Stake in Pfizer Inc. $PFE

US Bancorp DE lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 9.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,721,304 shares of the biopharmaceutical company’s stock after selling 491,946 shares during the quarter. US Bancorp DE’s holdings in Pfizer were worth $114,445,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Armstrong Fleming & Moore Inc purchased a new position in Pfizer during the second quarter valued at approximately $239,000. Tectonic Advisors LLC raised its position in shares of Pfizer by 22.1% during the second quarter. Tectonic Advisors LLC now owns 298,687 shares of the biopharmaceutical company’s stock valued at $7,240,000 after buying an additional 54,068 shares during the last quarter. Cohen Investment Advisors LLC raised its position in shares of Pfizer by 16.9% during the second quarter. Cohen Investment Advisors LLC now owns 103,490 shares of the biopharmaceutical company’s stock valued at $2,509,000 after buying an additional 14,984 shares during the last quarter. Vontobel Holding Ltd. raised its position in shares of Pfizer by 2.1% during the second quarter. Vontobel Holding Ltd. now owns 736,235 shares of the biopharmaceutical company’s stock valued at $17,846,000 after buying an additional 14,808 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its position in shares of Pfizer by 4.1% during the second quarter. Maryland State Retirement & Pension System now owns 276,125 shares of the biopharmaceutical company’s stock valued at $6,693,000 after buying an additional 10,986 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.3%

Shares of PFE opened at $25.67 on Thursday. The company’s fifty day moving average is $24.79 and its 200 day moving average is $24.15. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market capitalization of $145.95 billion, a PE ratio of 13.65, a P/E/G ratio of 0.86 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.